Drug intelligence / Profile preview

canakinumab + pembrolizumab

Development stage: Discontinued
Lead developer: Novartis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

Canakinumab + pembrolizumab is a combination therapy consisting of two immunotherapeutic agents. Canakinumab is a human monoclonal antibody that targets and neutralizes interleukin-1beta (IL-1β), an inflammatory cytokine, while pembrolizumab is a PD-1 inhibitor that enhances T-cell responses against tumor cells. This combination was developed to potentially enhance anti-tumor efficacy by simultaneously inhibiting pro-tumor inflammation and promoting immune responses against cancer cells.

Targets

PDCD1 (Programmed cell death protein 1 receptor)IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on canakinumab + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on canakinumab + pembrolizumab.

Explore the full profile